Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03377491




Registration number
NCT03377491
Ethics application status
Date submitted
6/12/2017
Date registered
19/12/2017
Date last updated
31/10/2024

Titles & IDs
Public title
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Scientific title
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Secondary ID [1] 0 0
EF-27
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreas Adenocarcinoma 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - NovoTTF-200T
Treatment: Drugs - Gemcitabine
Treatment: Drugs - nab paclitaxel

Experimental: NovoTTF-200T - Patients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel

Active comparator: Best Standard of Care - Patients receive best standard of care with gemcitabine and nab-Paclitaxel


Treatment: Devices: NovoTTF-200T
Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.

Treatment: Drugs: Gemcitabine
Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.

Treatment: Drugs: nab paclitaxel
nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
4 years
Secondary outcome [1] 0 0
Progression-free survival
Timepoint [1] 0 0
4 years
Secondary outcome [2] 0 0
Local progression-free survival
Timepoint [2] 0 0
4 years
Secondary outcome [3] 0 0
Objective response rate
Timepoint [3] 0 0
4 years
Secondary outcome [4] 0 0
One-year survival rate
Timepoint [4] 0 0
4 years
Secondary outcome [5] 0 0
Quality of life
Timepoint [5] 0 0
4 years
Secondary outcome [6] 0 0
Pain-free survival
Timepoint [6] 0 0
4 years
Secondary outcome [7] 0 0
Puncture-free survival
Timepoint [7] 0 0
4 years
Secondary outcome [8] 0 0
Resectability rate
Timepoint [8] 0 0
4 years
Secondary outcome [9] 0 0
Toxicity profile
Timepoint [9] 0 0
4 years

Eligibility
Key inclusion criteria
1. 18 years of age and older
2. Life expectancy of = 3 months
3. Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas
4. Unresectable, locally advanced stage disease according to the following criteria:

* Head/uncinate process:

1. Solid tumor contact with SMA>180°
2. Solid tumor contact with the CA>180°
3. Solid tumor contact with the first jejunal SMA branch
4. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t tumor or bland thrombus)
5. Contact with most proximal draining jejunal branch into SMV
* Body and tail

1. Solid tumor contact of >180° with the SMA or CA
2. Solid tumor contact with the CA and aortic involvement
3. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t tumor or bland thrombus)
* No distant metastasis, including non-regional lymph node metastasis
* No borderline resectable (per Al-Hawary MM, et al., Radiology 201414)
5. ECOG score 0-2
6. Amenable and assigned by the investigator to receive therapy with gemcitabine and nab-paclitaxel
7. Able to operate the NovoTTF-200T System independently or with the help of a caregiver
8. Signed informed consent form for the study protocol
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Prior palliative treatment (e.g. surgery, radiation) to the tumor
2. Cancer requiring anti-tumor treatment within the 5 years before inclusion, excluding treated stage I prostate cancer, in situ cervical or uterus cancer, in situ breast cancer and non-melanomatous skin cancer.
3. Serious co-morbidities:

1. Clinically significant (as determined by the investigator) hematological, hepatic and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x Upper Limit of Normal (ULN); AST and/or ALT > 2.5 x ULN; and serum creatinine > 1.5 x ULN.
2. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea).
3. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
4. History of cerebrovascular accident (CVA) within 6 months prior to randomization or that is not stable.
5. Active infection or serious underlying medical condition that would impair the ability of the patient to receive protocol therapy.
6. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent.
4. Concurrent anti-tumor therapy beyond gemcitabine and nab-paclitaxel
5. Implantable electronic medical devices in the torso, such as pacemakers
6. Known severe hypersensitivities to medical adhesives or hydrogel, or to one of the chemotherapies used in this trial.
7. Pregnancy or breast-feeding (female patients with reproductive potential and their partners must accept to use effective contraception throughout the entire study period and for 3 months after the end of treatment). All patients who are capable of becoming pregnant must take a pregnancy test which is negative within 72 hours before beginning treatment. The definition of effective contraception is left up to the decision of the investigator.
8. Unable to follow the protocol for medical, psychological, familial, geographic or other reasons.
9. Admitted to an institution by administrative or court order.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/02/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/10/2024
Sample size
Target
Accrual to date
Final
571
Recruitment in Australia
Recruitment state(s)
QLD,WA
Recruitment hospital [1] 0 0
Greenslopes Private Hospital - Greenslopes
Recruitment hospital [2] 0 0
St. John of God Murdoch Hospital - Murdoch
Recruitment hospital [3] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [4] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [5] 0 0
Westmead Hosptial - Westmead
Recruitment postcode(s) [1] 0 0
4120 - Greenslopes
Recruitment postcode(s) [2] 0 0
6150 - Murdoch
Recruitment postcode(s) [3] 0 0
VIC 3168 - Clayton
Recruitment postcode(s) [4] 0 0
NSW 2076 - Wahroonga
Recruitment postcode(s) [5] 0 0
NSW 2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
West Virginia
Country [31] 0 0
Austria
State/province [31] 0 0
Wörthersee
Country [32] 0 0
Austria
State/province [32] 0 0
Graz
Country [33] 0 0
Austria
State/province [33] 0 0
Salzburg
Country [34] 0 0
Austria
State/province [34] 0 0
Steyr
Country [35] 0 0
Belgium
State/province [35] 0 0
Anderlecht
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Woluwe-Saint-Lambert
Country [38] 0 0
Brazil
State/province [38] 0 0
Florianópolis
Country [39] 0 0
Brazil
State/province [39] 0 0
Ijuí
Country [40] 0 0
Brazil
State/province [40] 0 0
Porto Alegre
Country [41] 0 0
Brazil
State/province [41] 0 0
Ribeirão Preto
Country [42] 0 0
Brazil
State/province [42] 0 0
Rio De Janeiro
Country [43] 0 0
Brazil
State/province [43] 0 0
São Marcos
Country [44] 0 0
Brazil
State/province [44] 0 0
São Paulo
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
China
State/province [47] 0 0
Guangdong
Country [48] 0 0
China
State/province [48] 0 0
Heilongjiang
Country [49] 0 0
China
State/province [49] 0 0
Hubei
Country [50] 0 0
China
State/province [50] 0 0
Shaanxi
Country [51] 0 0
China
State/province [51] 0 0
Shandong
Country [52] 0 0
China
State/province [52] 0 0
Zhejiang
Country [53] 0 0
China
State/province [53] 0 0
Beijing
Country [54] 0 0
China
State/province [54] 0 0
Changchun
Country [55] 0 0
China
State/province [55] 0 0
Guangzhou
Country [56] 0 0
China
State/province [56] 0 0
Jilin
Country [57] 0 0
China
State/province [57] 0 0
Shanghai
Country [58] 0 0
China
State/province [58] 0 0
Shanxi
Country [59] 0 0
China
State/province [59] 0 0
Xingtai
Country [60] 0 0
China
State/province [60] 0 0
Zhengzhou
Country [61] 0 0
Croatia
State/province [61] 0 0
Zagreb
Country [62] 0 0
Czechia
State/province [62] 0 0
Brno Stred
Country [63] 0 0
Czechia
State/province [63] 0 0
Nový Jicín
Country [64] 0 0
Czechia
State/province [64] 0 0
Olomouc
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 2
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 8
Country [67] 0 0
France
State/province [67] 0 0
Bordeaux
Country [68] 0 0
France
State/province [68] 0 0
Angers cedex
Country [69] 0 0
France
State/province [69] 0 0
Lorient
Country [70] 0 0
France
State/province [70] 0 0
Lyon
Country [71] 0 0
France
State/province [71] 0 0
Paris
Country [72] 0 0
France
State/province [72] 0 0
Plérin
Country [73] 0 0
France
State/province [73] 0 0
Strasbourg
Country [74] 0 0
Germany
State/province [74] 0 0
Chemnitz
Country [75] 0 0
Germany
State/province [75] 0 0
Hannover
Country [76] 0 0
Germany
State/province [76] 0 0
Landshut
Country [77] 0 0
Germany
State/province [77] 0 0
Lingen
Country [78] 0 0
Germany
State/province [78] 0 0
Merseburg
Country [79] 0 0
Germany
State/province [79] 0 0
München
Country [80] 0 0
Germany
State/province [80] 0 0
Ulm
Country [81] 0 0
Hong Kong
State/province [81] 0 0
Hong Kong
Country [82] 0 0
Hungary
State/province [82] 0 0
Budapest
Country [83] 0 0
Hungary
State/province [83] 0 0
Gyula
Country [84] 0 0
Hungary
State/province [84] 0 0
Kecskemét
Country [85] 0 0
Hungary
State/province [85] 0 0
Szekszárd
Country [86] 0 0
Hungary
State/province [86] 0 0
Szolnok
Country [87] 0 0
Israel
State/province [87] 0 0
Haifa
Country [88] 0 0
Israel
State/province [88] 0 0
Petah tikva
Country [89] 0 0
Israel
State/province [89] 0 0
Ramat Gan
Country [90] 0 0
Israel
State/province [90] 0 0
Tel Aviv
Country [91] 0 0
Italy
State/province [91] 0 0
Alessandria
Country [92] 0 0
Italy
State/province [92] 0 0
Firenze
Country [93] 0 0
Italy
State/province [93] 0 0
Roma
Country [94] 0 0
Italy
State/province [94] 0 0
Torino
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Busan
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Gyeonggi-do
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Daegu
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Hwasun
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Incheon
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Seongnam-si
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Suwon
Country [103] 0 0
Mexico
State/province [103] 0 0
Chih.
Country [104] 0 0
Mexico
State/province [104] 0 0
NL
Country [105] 0 0
Mexico
State/province [105] 0 0
Sinaloa
Country [106] 0 0
Mexico
State/province [106] 0 0
Aguascalientes
Country [107] 0 0
Mexico
State/province [107] 0 0
Cuauhtémoc
Country [108] 0 0
Mexico
State/province [108] 0 0
Cuautitlán Izcalli
Country [109] 0 0
Mexico
State/province [109] 0 0
Estado De México
Country [110] 0 0
Mexico
State/province [110] 0 0
Monterrey
Country [111] 0 0
Mexico
State/province [111] 0 0
Puebla
Country [112] 0 0
Mexico
State/province [112] 0 0
San Luis Potosí
Country [113] 0 0
Mexico
State/province [113] 0 0
Toluca de Lerdo
Country [114] 0 0
Mexico
State/province [114] 0 0
Toluca De Lerdo
Country [115] 0 0
Mexico
State/province [115] 0 0
Veracruz
Country [116] 0 0
Poland
State/province [116] 0 0
Poznan
Country [117] 0 0
Poland
State/province [117] 0 0
Rzeszów
Country [118] 0 0
Poland
State/province [118] 0 0
Warsaw
Country [119] 0 0
Poland
State/province [119] 0 0
Wroclaw
Country [120] 0 0
Spain
State/province [120] 0 0
Barcelona
Country [121] 0 0
Spain
State/province [121] 0 0
Elche
Country [122] 0 0
Spain
State/province [122] 0 0
Madrid
Country [123] 0 0
Spain
State/province [123] 0 0
Málaga
Country [124] 0 0
Spain
State/province [124] 0 0
Pamplona
Country [125] 0 0
Spain
State/province [125] 0 0
Santander
Country [126] 0 0
Spain
State/province [126] 0 0
Valencia
Country [127] 0 0
Switzerland
State/province [127] 0 0
Fribourg
Country [128] 0 0
Switzerland
State/province [128] 0 0
Winterthur

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
NovoCure Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03377491